“But at the time, and this was in about 2017, the capital markets had kind of shifted focus slightly away from platform development in the genomics field and much more into the applications of genomics. And the reality is it's an incredibly capital intensive field. And we look at companies that are launching DNA sequencing platforms now, and they have raised between $500 million to billion in private investment, even prior to market launch.”